Latest News

Key Insights Insiders appear to have a vested interest in Great Rich Technologies' growth, as seen by their sizeable...

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

JK Synapse Co., Ltd. ( KOSDAQ:060230 ) shares have had a really impressive month, gaining 33% after a shaky period...

Cohen & Steers, Inc. reported past fourth-quarter 2025 results, with revenue rising to US$143.8 million while net income and earnings per share from continuing operations declined year on year. Alongside the earnings, the firm highlighted continued positive investment flows, a strong institutional pipeline, and appointed Diana Shieh to lead and scale its private real estate asset management platform. Next, we examine how these developments, particularly the expanding institutional pipeline,...

TechnipFMC (FTI) is back in focus after the board approved a roughly US$2.00b share repurchase program and the company reported fresh subsea and iEPCI contract awards with bp, Eni, and Chevron. See our latest analysis for TechnipFMC. At a share price of US$54.26, TechnipFMC has seen a 21.52% 1 month share price return and a 33.91% 3 month share price return. Its 1 year total shareholder return of 73.89% and very large 5 year total shareholder return highlight momentum that recent contract...

In January 2026, a consortium led by Amentum won a framework contract worth up to US$207 million to provide program management and technical solutions for planning and developing up to two gigawatt-scale nuclear power plants in the Netherlands, while Amentum was also selected as program delivery partner for early Rolls-Royce SMR deployments in the UK and Czech Republic. Together, these projects highlight Amentum’s expanding role across both large conventional nuclear builds and emerging SMR...

Why Kerrisdale’s short report and the bank application matter for Affirm Kerrisdale Capital’s recent short report on Affirm Holdings (AFRM), paired with the company’s application to launch an FDIC insured industrial loan company, has put the stock’s credit profile and long term funding model squarely in focus. See our latest analysis for Affirm Holdings. Those headlines have landed against a choppy backdrop, with a 1 day share price return of 1.93% decline and a 30 day share price return of...

Why RH (RH) Is Back On Watch For Investors RH (RH) has recently drawn fresh attention after a sharp move in its share price, with the stock up around 23% over the past month and roughly 21% in the past 3 months. That price action stands in contrast to a total return decline of about 45% over the past year and weaker multi year returns. This has prompted investors to reassess how the company’s current fundamentals and valuation line up with expectations. See our latest analysis for RH. Even...

SL's (KRX:005850) stock is up by a considerable 55% over the past three months. Since the market usually pay for a...

Earlier in January 2026, Skyward Specialty Insurance Group, Inc. expanded its E&S Property offering by adding Excess coverage aimed at technically complex, non-catastrophe property risks and layered programs. This move, aligned with the carrier’s “Rule Our Niche” focus and recent leadership changes in Inland Marine and Transactional E&S, underscores its effort to address areas where traditional insurance markets fall short. Next, we’ll examine how the added Excess E&S Property capacity...

What sparked the latest move in ServisFirst Bancshares (SFBS)? ServisFirst Bancshares (SFBS) shares moved sharply after fourth quarter 2025 earnings topped revenue and profit forecasts, with management pointing to loan growth, wider net interest margins, tighter costs, and a higher dividend. See our latest analysis for ServisFirst Bancshares. The recent earnings jump and dividend increase came after a period where the share price has been firming, with a 30 day share price return of 11.41%...

Genscript Biotech (SEHK:1548) is back in focus after its associate Legend Biotech reported approximately US$555 million in Q4 2025 net trade sales of multiple myeloma cell therapy CARVYKTI®, underscoring meaningful commercial traction. See our latest analysis for Genscript Biotech. Legend Biotech’s CARVYKTI® sales update has arrived after a mixed year for Genscript Biotech, with the share price at HK$13.3, a year to date share price return of 3.99%, a 1 year total shareholder return of 26.19%...

Lichtensteinische Landesbank (SWX:LLBN) and LGT have created the Liechtensteinisches Pfandbriefinstitut, giving the country a shared platform to issue covered bonds backed by first lien mortgages on local real estate. See our latest analysis for Liechtensteinische Landesbank. LLB’s recent role in setting up the Pfandbriefinstitut comes as momentum in the shares has been strong, with a 12.65% 1 month share price return and a 31.98% 1 year total shareholder return. This suggests investors are...

Mitsubishi Motors (TSE:7211) shares are in focus after the Board approved changes to top management, with Keisuke Kishiura named President & COO and Takao Kato moving to the CEO role. See our latest analysis for Mitsubishi Motors. The executive reshuffle comes after a mixed period for investors, with the share price at ¥391.8 and a 30 day share price return of 5.04% contrasted with a 1 year total shareholder return decline of 9.92%. This suggests shorter term momentum against weaker longer...

Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑stage trial to test multiple doses. This designation could shorten regulatory timelines and enhance pemvidutide’s profile in the competitive MASH treatment landscape, potentially reshaping Altimmune’s long‑term product mix and risk profile. Next, we’ll examine how pemvidutide’s Breakthrough...

Sterling Infrastructure’s E-Infrastructure segment, which includes data center construction, has recently been highlighted as the key engine of the business, with commentary emphasizing its strong underlying fundamentals and connection to AI-related capacity needs. An interesting insight is that some analysts view data center and AI infrastructure demand as sufficiently durable to counter concerns about an AI spending bubble, placing this segment at the heart of Sterling Infrastructure’s...

EMBARK readout puts ELEVIDYS back in focus Sarepta Therapeutics (SRPT) is back on investor radars after the company scheduled a January 26 webcast to share 3 year topline functional outcomes from the EMBARK Phase 3 ELEVIDYS trial in Duchenne muscular dystrophy. See our latest analysis for Sarepta Therapeutics. At a share price of US$21.13, Sarepta’s recent performance has been weak, with a 30 day share price return of 4.5% decline and a 1 year total shareholder return of 81.9% loss. This...

Altus Group (TSX:AIF) is back in focus after Cushman & Wakefield agreed to roll out the company’s ARGUS Intelligence platform globally to support valuation and performance analysis across its commercial real estate operations. See our latest analysis for Altus Group. The Cushman & Wakefield rollout comes at a time when Altus Group’s share price has retreated. The 30 day share price return is 12.30% and the year to date share price return is 11.81%. The 1 year total shareholder return is...

Why the Savara (SVRA) story is back in focus The latest headline around Savara (SVRA) centers on a law firm investigation into potential fiduciary duty breaches, following a class action tied to the FDA’s refusal of the company’s MOLBREEVI Biologics License Application. See our latest analysis for Savara. The legal scrutiny arrives after a sharp reaction to the FDA’s MOLBREEVI decision. At the same time, the stock’s 90 day share price return of 37.44% and 1 year total shareholder return of...

Why Erasca’s latest equity raise matters for current and prospective shareholders Erasca (ERAS) has closed an upsized follow on equity offering, raising about US$225 million by selling 22,500,000 common shares at US$10.00, a move that directly affects existing and future shareholders. See our latest analysis for Erasca. The equity raise comes after a sharp re-rating in the stock, with a 30 day share price return of 186.21% and a year to date share price return of 177.44%. The 1 year total...

Key Insights The projected fair value for LS is ₩186,655 based on 2 Stage Free Cash Flow to Equity LS' ₩228,000 share...

Clorox (NYSE:CLX) has agreed to acquire GOJO Industries, the privately held maker of Purell hand sanitizer. The deal brings the Purell brand into Clorox’s health and hygiene portfolio, expanding its presence in both institutional and retail channels. The acquisition is aligned with Clorox’s IGNITE strategy and is expected to create meaningful synergies across its fastest growing and most profitable segment. For investors watching NYSE:CLX, this move comes with the stock at a share price of...

Hotel performance update and why it matters for Star Asia Investment (TSE:3468) Star Asia Investment (TSE:3468) recently reported strong December 2025 hotel performance, with record inbound tourism to Japan, resilient Southeast Asian demand, and government campaigns supporting occupancy and revenue across its portfolio. See our latest analysis for Star Asia Investment. Despite the strong hotel performance, the 7 day share price return of a 2.98% decline and recent softness suggest some...

Why V2X is back on investor radars V2X (VVX) has drawn fresh attention after advancing to Phase II of the US Army's Flight School Next competition and securing a role under the Missile Defense Agency's SHIELD contract vehicle. See our latest analysis for V2X. The SHIELD award and Flight School Next progress come as momentum in the shares has picked up, with a 25.4% 1 month share price return and a 25.8% year to date share price return, alongside a 1 year total shareholder return of 31.6%. If...